Company Interview / LTR Pharma sniffs out new solution for digestive disorders

LTR Pharma (ASX: LTP), a clinical stage biopharmaceutical company, collaborates with Strategic Drug Solutions to develop a nasal spray targeting esophageal motility disorders. Lee Rodne from LTR emphasises the high prevalence of these disorders, affecting 20% of individuals over 50, highlighting the need for non-invasive treatments.

Lee highlights the $4.5 billion global market for OMD treatments, with the US being a major focus. Their nasal spray technology aims to offer a more efficient and convenient alternative compared to current invasive procedures. The company aims to bring this innovative product to the Australian market soon, alongside expanding into Europe, Asia, and South America.

LTR Pharma (ASX: LTP) also continues its success with other nasal spray products, like Spontan, for erectile dysfunction. With a strong cash position of $34 million, the company is poised for further market launches, including the US market in 2026, showcasing their commitment to revolutionising drug delivery.